Arrowstreet Capital, Limited Partnership Atea Pharmaceuticals, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $326,094 - $514,030	101,587 New	101,587 $380,000
Q2 2022 Aug 15, 2022	BUY	$5.33 - $8.18 $57,979 - $88,982	10,878 New	10,878 $77,000
Q1 2022 May 13, 2022	SELL	$5.5 - $9.19 $565,262 - $944,502	-102,775 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.67 - $44.59 $581,232 - $3.38 Million	-75,780 Reduced 42.44%	102,775 $919,000
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $1.02 Million - $1.67 Million	47,695 Added 36.45%	178,555 $6.26 Million
Q2 2021 Aug 13, 2021	BUY	$19.22 - $59.08 $2.52 Million - $7.73 Million	130,860 New	130,860 $2.81 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $281M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.